• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Shortened tuberculosis treatment regimen inferior to standard

byMatthew Sibbald, MD, PhD
October 24, 2014
in Chronic Disease, Infectious Disease, Public Health, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with pulmonary tuberculosis receiving a shortened, 4-month treatment regimen with gatifloxacin were more likely to experience an unfavourable outcome at 24 months than patients receiving the standard 6-month regimen.

2. Patients in the experimental group were less likely to have treatment failure but were more likely to have a recurrence of tuberculosis than those receiving standard therapy,

Evidence Rating Level: 1 (Excellent)

Study Rundown: Although the incidence and mortality rates of tuberculosis peaked a decade ago, the disease remains a public health challenge. Millions of individuals are still affected each year and the incidence of multi-drug resistant tuberculosis (MDR-TB) is rising, as a result of failure to complete treatment course or inappropriate use of drug therapies. The standard treatment of tuberculosis requires 6 months of multiple antimicrobial medications. Fluoroquinolones have shown promise in shortening the duration of treatment and have been investigated in attempts to improve treatment adherence.

This phase 3 trial randomized patients to a 4-month treatment regimen with the fluoroquinolone, gatifloxacin, or the standard 6-month regimen using ethambutol during the initial phase of management. The study was unable to show noninferiority of a 4-month regimen with gatifloxacin compared to the standard 6-month regimen. It is possible that drug levels were insufficient to demonstrate the true effect of the experimental regimen since a standard dose of gatifloxacin was given without adjustment according to body weight. Overall, the use of a composite outcome that included outcomes of varying severity made the findings difficult to interpret. Although promising in phase 2 trials, shortened fluoroquinolone-containing treatment regimens have failed to show noninferiority compared to the standard regimen thus far.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

RELATED REPORTS

#VisualAbstract: Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

Oral BPaLM regimen is noninferior to standard of care for rifampin-resistant tuberculosis

Relevant Reading: Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

In-Depth [randomized controlled trial]: This phase 3, open-label, randomized controlled trial included 1836 patients with smear-positive, rifampin-sensitive pulmonary tuberculosis in 5 countries in sub-Saharan Africa. Patients were randomized to a standard 6-month regimen including a 2-month intensive treatment phase with ethambutol, or the experimental 4-month regimen substituting 400 mg gatifloxacin per day for ethambutol during the intensive phase and continued for the duration of treatment. The primary outcome was a composite of treatment failure, recurrence, death, or study dropout, measured at 24 months after the end of treatment.

Modified intention-to-treat analysis of the primary outcome in 1356 patients showed a risk difference of 3.5 percentage points (experimental group minus control group; 95% CI, -0.7 to 7.7). The per-protocol analysis demonstrated an adjusted difference of 5.5 percentage points (experimental group minus control group; 95% CI, 1.6 to 9.4). Treatment failure occurred more frequently in the control group compared to the experimental group (2.4% vs. 1.7%); however, more patients in the experimental group had a recurrence of tuberculosis (14.6% vs. 7.1%).

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: gatifloxacintuberculosis
Previous Post

Group B streptococcus infections on the rise despite prevention guidelines

Next Post

Quantitative MRI may differentiate true from pseudoprogression in glioblastoma

RelatedReports

StudyGraphics

#VisualAbstract: Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

March 23, 2023
Quick Take: Discovery and validation of a prognostic proteomic signature for tuberculosis progression
Chronic Disease

Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

March 17, 2023
Shorter moxifloxacin-containing regimens ineffective for treating TB [REMoxTB trial]
Chronic Disease

Oral BPaLM regimen is noninferior to standard of care for rifampin-resistant tuberculosis

January 4, 2023
Quick Take: Discovery and validation of a prognostic proteomic signature for tuberculosis progression
Chronic Disease

Two bedaquiline-containing regimens had superior efficacy and safety profiles for treatment of rifampin-resistant tuberculosis

December 7, 2022
Next Post
Quantitative MRI may differentiate true from pseudoprogression in glioblastoma

Quantitative MRI may differentiate true from pseudoprogression in glioblastoma

STIs and recreational drug use prevalent among swingers

STIs and recreational drug use prevalent among swingers

Trials in the German Democratic Republic suggested to be ethically ambiguous

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Addition of fludrocortisone to hydrocortisone is beneficial in management of septic shock
  • Surveillance testing of staff at nursing facilities reduces resident COVID-19 mortality
  • Childhood maltreatment may cause mental health problems
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options